Form 4: Surmodics Insider Reports Share, Option Conversion Post-Merger

Surmodics Inc. VP Finance, Corp. Controller John D. Manders reported the conversion of his common stock, RSUs, and stock options into cash following the company's acquisition by BCE Parent, LLC.

Summary

• John D. Manders, VP Finance, Corp. Controller of Surmodics Inc. (SRDX), reported changes in beneficial ownership due to a merger.
• Surmodics Inc. was acquired by BCE Parent, LLC and BCE Merger Sub, Inc. via a Merger Agreement dated May 28, 2024.
• At the effective time of the merger, each share of Surmodics common stock was cancelled and converted into the right to receive $43.00 per share in cash.
• All outstanding restricted stock units (RSUs) held by Manders vested immediately prior to the merger and were converted into cash at $43.00 per share.
• Unexercised stock options were cancelled and converted into a cash payment equal to the product of the number of shares subject to the option multiplied by the excess of the $43.00 merger consideration over the option's exercise price.
• Following the merger, Manders no longer beneficially owns, directly or indirectly, any shares of common stock or derivative securities of Surmodics Inc.

Sentiment

Score: 7

Explanation: The filing reports a completed acquisition where shareholders received a cash payout, which is generally a positive liquidity event for investors. However, it also signifies the end of Surmodics as an independent public entity, which could be seen as neutral or slightly negative for those who preferred its long-term growth potential as a standalone company. The insider's equity was converted to cash, indicating a successful exit for their holdings.

Positives

• The reporting person received cash for common stock, vested RSUs, and in-the-money stock options, indicating a liquidity event.
• The merger consideration of $43.00 per share provided a clear, definitive valuation for equity holders.

Negatives

• Surmodics Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary.
• Former public shareholders no longer hold equity in Surmodics Inc.

Future Outlook

The filing reports a completed merger transaction, resulting in Surmodics Inc. becoming a wholly-owned subsidiary. As such, there are no forward-looking statements or guidance for the former public entity.

Industry Context

This filing reflects a completed acquisition in the medical device or life sciences industry, where Surmodics Inc. operated. Such mergers are common as larger entities seek to consolidate market share, acquire technology, or achieve synergies. The cash consideration indicates a definitive exit for public shareholders.

Comparison to Industry Standards

• The merger consideration of $43.00 per share would typically be evaluated against the company's historical stock price, analyst price targets, and valuations of comparable companies in the medical device or life sciences sector at the time of the merger agreement (May 28, 2024).
• Without specific details on the valuation multiples (e.g., EV/EBITDA, P/E) or comparable transactions, a detailed assessment against global benchmarks is not possible from this Form 4 alone. However, the cash payout provides a clear, final value for shareholders.

Stakeholder Impact

• Shareholders: Received $43.00 per share in cash for their common stock, losing their equity stake in Surmodics Inc.
• Reporting Person (John D. Manders): His common stock, vested RSUs, and in-the-money stock options were converted to cash.

Next Steps

• No future actions or milestones for Surmodics Inc. as a public entity are mentioned, given its acquisition.
• The reporting person has no further beneficial ownership to report for Surmodics Inc.

Key Dates

Keywords

Surmodics Inc., SRDX, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Cash Out, BCE Parent LLC